查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1575543

Eylea 市场：按治疗层级、给药方法、患者类型、最终用户分类 - 全球预测 2025-2030

Eylea Market by Therapeutic Class (Age-Related Macular Degeneration, Diabetic Macular Edema, Retinal Disorders), Mode Of Administration (Intravitreal Injection, Ocular Implants), Patient Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年Eylea市场估值为68.9亿美元，预计2024年将达72.5亿美元，复合年增长率为6.83%，预计2030年将达到109.5亿美元。

Eylea（阿柏西普）在眼科药品市场主要专注于老龄化黄斑部病变（AMD）、糖尿病黄斑部水肿（DME）、视网膜静脉阻塞（RVO）等视网膜疾病的治疗。这项需求是由对有效治疗方法的需求所驱动的，这些治疗旨在解决全球老龄化人口和糖尿病患者在管理视力障碍方面未得到满足的关键需求。作为注射治疗，Eylea 因其经过验证的功效和安全性而赢得了信心，并主要被眼科医生广泛接受和应用。最终用途包括进行此类治疗的诊所、医院和门诊服务中心。影响该市场的主要成长要素包括视网膜疾病发病率的增加、药物配方的持续进步以及人们对眼睛健康的认识不断提高。最近的潜在商机包括进一步纳入联合治疗和扩大适应症以占领更广泛的市场。这可以透过旨在提高疗效和减少副作用的策略研究伙伴关係和临床试验来实现。然而，市场成长面临限制，例如治疗成本高、监管环境严格以及生物相似药和替代疗法的竞争加剧，这可能会影响定价和市场占有率。创新的最佳领域包括增强缓释性製剂等给药机制，以提高患者的便利性和依从性。另一个有前景的领域是利用人工智慧和机器学习来提高诊断准确性和个人化治疗。市场的本质是动态的，受到科学进步和需要不断适应的竞争压力的驱动。公司可以透过专注于竞争较少的新兴市场并与医院和医疗保健提供者形成策略联盟来更好地定位自己。此外，投资教育行销宣传活动可以提高医疗保健提供者和患者对 Eylea 益处的认识，并提高市场渗透率。

主要市场统计
基准年[2023] 68.9亿美元
预测年份 [2024] 72.5亿美元
预测年份 [2030] 109.5亿美元
复合年增长率（%） 6.83%

市场动态：揭示快速发展的 Eylea 市场的关键市场洞察

Eylea 市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 新兴国家医疗保健基础设施的扩张提高了 Eylea 治疗的可近性
    • 製药公司之间的合作和伙伴关係，以加速 Eylea 的开发和分销
    • 全球老年人口的增加导致 Eylea 可治疗的视网膜疾病发生率上升
    • 增加对创新眼科解决方案研发活动的投资，以支持 Eylea 市场成长
  • 市场限制因素
    • 患者获得先进抗 VEGF 疗法的机会和负担能力有限
    • 由于新兴生物相似药的竞争加剧，现有品牌的市场占有率下降
  • 市场机会
    • 制定病患教育计画以提高对视网膜疾病管理的了解
    • 利用巨量资料分析进行视网膜疾病的早期发现与监测
    • 推广居家照护解决方案以提高病患便利性和依从性
  • 市场挑战
    • 视网膜疾病替代治疗方案的竞争对 Eylea市场占有率的影响
    • 影响 Eylea 在每个地区行销和分销的监管和合规挑战

波特五力：驾驭 Eylea 市场的策略工具

波特的五力框架是了解 Eylea 市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 Eylea 市场的外部影响

外部宏观环境因素在塑造 Eylea 市场的业绩动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解 Eylea 市场的竞争状况

Eylea 市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵 Eylea 市场供应商的绩效评估

FPNV 定位矩阵是评估 Eylea 市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议绘製 Eylea 市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，Eylea 市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 扩大新兴国家的医疗基础设施改善获得 Eylea 治疗的机会
      • 製药公司之间的合作和联盟加速了 Eylea 的开发和分销
      • 随着世界各地人口持续老化，视网膜疾病的发生率不断增加。艾利亚
      • 增加对创新眼科解决方案研发活动的投资，以支持 Eylea 市场成长
    • 抑制因素
      • 先进抗 VEGF 疗法的患者获取机会和费用有限
      • 由于新兴生物相似药的竞争加剧，现有品牌的市场占有率正在下降
    • 机会
      • 制定病患教育计画以提高对视网膜疾病管理的了解
      • 利用巨量资料分析早期发现并监测视网膜疾病
      • 推广居家照护解决方案，提升病患便利性和依从性
    • 任务
      • 视网膜疾病替代治疗方案的竞争影响了 Eylea 的市场占有率
      • 影响 Eylea 在各个地区行销和分销的监管和合规挑战
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第 6 章 Eylea 市集（依治疗层级）

  • 老龄化黄斑部病变
  • 糖尿病黄斑部水肿
  • 视网膜疾病

第七章 Eylea 市场管理方式

  • 玻璃体内注射
  • 眼内植入
    • 生物分解性
    • 不可生物分解性

第 8 章 Eylea 市场（依病患类型）

  • 成人用
  • 老年病
  • 小儿科

第 9 章 Eylea 市场：依最终用户分类

  • 门诊手术中心
  • 医院
  • 眼科诊所

第10章 美洲Eylea市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章 亚太地区Eylea市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲Eylea市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C04F0

The Eylea Market was valued at USD 6.89 billion in 2023, expected to reach USD 7.25 billion in 2024, and is projected to grow at a CAGR of 6.83%, to USD 10.95 billion by 2030.

Eylea (aflibercept) operates within the ophthalmology pharmaceutical market, primarily focusing on treating retinal diseases such as age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Its necessity stems from the demand for effective therapies that address the significant unmet need for managing vision impairment in the aging global population and among diabetic patients. Applied as an injectable treatment, Eylea has gained trust due to its proven efficacy and safety profile, contributing to its widespread acceptance and application primarily among ophthalmologists. The end-use scope encompasses clinics, hospitals, and ambulatory service centers where such treatments are administered. Key growth factors influencing this market include a growing incidence of retinal diseases, continuous advancements in drug formulations, and expanding awareness about eye health. Recent potential opportunities include its further inclusion in combination therapies and expanding indications to capture wider markets. This could be achieved through strategic research partnerships and clinical trials, aiming to enhance efficacy and reduce side effects. However, market growth faces limitations such as high treatment costs, stringent regulatory scenarios, and increasing competition from biosimilars and alternative therapies which may affect pricing and market share. The best areas for innovation include enhancing delivery mechanisms, like sustained-release formulations, to improve patient convenience and compliance. Another promising area is the use of artificial intelligence and machine learning to improve diagnostic accuracy and treatment personalization. The market's nature is dynamic, driven by scientific advancements and competitive pressures that necessitate continuous adaptation. For businesses, focusing on capturing emerging markets with lower competition and creating strategic alliances with hospitals and healthcare providers can position them favorably. Moreover, investing in educational marketing campaigns can boost market penetration by raising awareness of Eylea's benefits among healthcare providers and patients alike.

KEY MARKET STATISTICS
Base Year [2023] USD 6.89 billion
Estimated Year [2024] USD 7.25 billion
Forecast Year [2030] USD 10.95 billion
CAGR (%) 6.83%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Eylea Market

The Eylea Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expansion of healthcare infrastructure in emerging economies enhancing accessibility to Eylea treatments
    • Collaborations and partnerships among pharmaceutical companies accelerating development and distribution of Eylea
    • Growing elderly population globally contributing to higher incidence of retinal disorders treatable by Eylea
    • Increased investment in research and development activities for innovative ophthalmic solutions supporting Eylea market growth
  • Market Restraints
    • Limited patient accessibility and affordability of advanced anti-VEGF therapies
    • Increasing competition from emerging biosimilars reducing market share of established brands
  • Market Opportunities
    • Developing patient education programs to enhance understanding of retinal disease management
    • Leveraging big data analytics for early detection and monitoring of retinal conditions
    • Promoting home-based care solutions to increase patient convenience and adherence
  • Market Challenges
    • Competition from alternative treatment options for retinal diseases impacting Eylea's market share
    • Regulatory and compliance challenges affecting the marketing and distribution of Eylea in different regions

Porter's Five Forces: A Strategic Tool for Navigating the Eylea Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Eylea Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Eylea Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Eylea Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Eylea Market

A detailed market share analysis in the Eylea Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Eylea Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Eylea Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Eylea Market

A strategic analysis of the Eylea Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Eylea Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alcon Inc., Alexion Pharmaceuticals, Inc., Allergan, Inc., Amgen Inc., Astellas Pharma Inc., Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Eylea Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapeutic Class, market is studied across Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Disorders.
  • Based on Mode Of Administration, market is studied across Intravitreal Injection and Ocular Implants. The Ocular Implants is further studied across Biodegradable and Non-Biodegradable.
  • Based on Patient Type, market is studied across Adult, Geriatric, and Pediatric.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, and Ophthalmic Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expansion of healthcare infrastructure in emerging economies enhancing accessibility to Eylea treatments
      • 5.1.1.2. Collaborations and partnerships among pharmaceutical companies accelerating development and distribution of Eylea
      • 5.1.1.3. Growing elderly population globally contributing to higher incidence of retinal disorders treatable by Eylea
      • 5.1.1.4. Increased investment in research and development activities for innovative ophthalmic solutions supporting Eylea market growth
    • 5.1.2. Restraints
      • 5.1.2.1. Limited patient accessibility and affordability of advanced anti-VEGF therapies
      • 5.1.2.2. Increasing competition from emerging biosimilars reducing market share of established brands
    • 5.1.3. Opportunities
      • 5.1.3.1. Developing patient education programs to enhance understanding of retinal disease management
      • 5.1.3.2. Leveraging big data analytics for early detection and monitoring of retinal conditions
      • 5.1.3.3. Promoting home-based care solutions to increase patient convenience and adherence
    • 5.1.4. Challenges
      • 5.1.4.1. Competition from alternative treatment options for retinal diseases impacting Eylea's market share
      • 5.1.4.2. Regulatory and compliance challenges affecting the marketing and distribution of Eylea in different regions
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Eylea Market, by Therapeutic Class

  • 6.1. Introduction
  • 6.2. Age-Related Macular Degeneration
  • 6.3. Diabetic Macular Edema
  • 6.4. Retinal Disorders

7. Eylea Market, by Mode Of Administration

  • 7.1. Introduction
  • 7.2. Intravitreal Injection
  • 7.3. Ocular Implants
    • 7.3.1. Biodegradable
    • 7.3.2. Non-Biodegradable

8. Eylea Market, by Patient Type

  • 8.1. Introduction
  • 8.2. Adult
  • 8.3. Geriatric
  • 8.4. Pediatric

9. Eylea Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Hospitals
  • 9.4. Ophthalmic Clinics

10. Americas Eylea Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Eylea Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Eylea Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alcon Inc.
  • 3. Alexion Pharmaceuticals, Inc.
  • 4. Allergan, Inc.
  • 5. Amgen Inc.
  • 6. Astellas Pharma Inc.
  • 7. Bayer AG
  • 8. Biogen Inc.
  • 9. Bristol-Myers Squibb Company
  • 10. Eli Lilly and Company
  • 11. Genentech, Inc.
  • 12. GlaxoSmithKline plc
  • 13. Johnson & Johnson
  • 14. Merck & Co., Inc.
  • 15. Novartis International AG
  • 16. Pfizer Inc.
  • 17. Regeneron Pharmaceuticals, Inc.
  • 18. Roche Holding AG
  • 19. Sanofi S.A.
  • 20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. EYLEA MARKET RESEARCH PROCESS
  • FIGURE 2. EYLEA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL EYLEA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL EYLEA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL EYLEA MARKET SIZE, BY PATIENT TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL EYLEA MARKET SIZE, BY PATIENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL EYLEA MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL EYLEA MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES EYLEA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES EYLEA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EYLEA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. EYLEA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. EYLEA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL EYLEA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL EYLEA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL EYLEA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. EYLEA MARKET DYNAMICS
  • TABLE 7. GLOBAL EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL EYLEA MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL EYLEA MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL EYLEA MARKET SIZE, BY RETINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL EYLEA MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL EYLEA MARKET SIZE, BY OCULAR IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL EYLEA MARKET SIZE, BY BIODEGRADABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL EYLEA MARKET SIZE, BY NON-BIODEGRADABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL EYLEA MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL EYLEA MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL EYLEA MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL EYLEA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL EYLEA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL EYLEA MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS EYLEA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES EYLEA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC EYLEA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. MALAYSIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. PHILIPPINES EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. SINGAPORE EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. SOUTH KOREA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. TAIWAN EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. THAILAND EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. VIETNAM EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA EYLEA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. DENMARK EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. EGYPT EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. FINLAND EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. FRANCE EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. GERMANY EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. ISRAEL EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. ITALY EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. NETHERLANDS EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. NIGERIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. NORWAY EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. POLAND EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. QATAR EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. RUSSIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. SAUDI ARABIA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH AFRICA EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. SPAIN EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. SWEDEN EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 214. SWITZERLAND EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. TURKEY EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. UNITED ARAB EMIRATES EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED KINGDOM EYLEA MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM EYLEA MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM EYLEA MARKET SIZE, BY OCULAR IMPLANTS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM EYLEA MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM EYLEA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. EYLEA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 235. EYLEA MARKET, FPNV POSITIONING MATRIX, 2023